MMAD (Demethyldolastatin 10) video
MMAD (Demethyldolastatin 10) basic Characters
|Storage Temp:||Powder -20°C 3 years |
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
|Color:||White to off-white(solid)|
MMAD(Demethyldolastatin 10) (203849-91-6) usage in steroids cycle
Synonyms: Demethyldolastatin 10 (203849-91-6);Monomethylauristatin D;Monomethyl Dolastatin 10
Chemical Name: (S)-N-((3R,4S,5S)-3-methoxy-1-((S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)propyl)pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide
Warning on MMAD(Demethyldolastatin 10)
Product has not been fully validated for medical applications. For research use only
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
In Vitro: MMAD(Demethyldolastatin 10) (203849-91-6) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity
In Vivi: The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats.
How to buy MMAD ; buy Demethyldolastatin 10 from AASraw
1.To contact us by our email inquiry system,or online skypecustomer service representative(CSR).
2.To provide us your inquired quantity and address.
3.Our CSR will provide you the quotation, payment term, tracking number, delivery ways and estimated arrival date(ETA).
4.Payment done and the goods will be sent out in 12 hours(For order within 10kg).
5.Goods received and give comments.